Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.
In conclusion, over-exuberant anti-viral immune responses in older patients with COVID-19 may pose a substantial risk to patient survival and mitigation against such hyper-inflammation with PDE4i, especially with anti-viral agents, is a strategy that need to be pursed, especially in older patients.
PMID: 32558435 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
More News: Chemistry | Chronic Obstructive Pulmonary | Coronavirus | COVID-19 | General Medicine | Israel Health | Middle East Health | Pneumonia | Respiratory Medicine | Rheumatology | Skin